Biomerica, Inc. (NASDAQ:BMRA) Sees Large Increase in Short Interest

Biomerica, Inc. (NASDAQ:BMRA) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totaling 41,348 shares, a growth of 39.5% from the November 30th total of 29,633 shares. Approximately 1.7% of the company’s stock are short sold. Based on an average daily volume of 23,098 shares, the short-interest ratio is presently 1.8 days. Based on an average daily volume of 23,098 shares, the short-interest ratio is presently 1.8 days. Approximately 1.7% of the company’s stock are short sold.

Biomerica Trading Up 1.4%

Shares of NASDAQ BMRA traded up $0.04 during mid-day trading on Wednesday, reaching $2.49. The company had a trading volume of 13,402 shares, compared to its average volume of 479,177. The firm has a 50 day simple moving average of $2.51 and a two-hundred day simple moving average of $2.91. The stock has a market cap of $7.33 million, a P/E ratio of -2.59 and a beta of 0.06. Biomerica has a 52-week low of $2.11 and a 52-week high of $10.16.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Biomerica in a research note on Tuesday, October 14th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Biomerica Company Profile

Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.